BSMI POLYMORPHISM OF VITAMIN D RECEPTOR GENE AND EFFICIENCY OF POST- MENOPAUSAL OSTEOPOROSIS TREATMENT BY IBANDRONIC ACID
Author:
Reznichenko N.1, Adunts A.2
Affiliation:
1. V.I. Vernadsky Crimean Federal University 2. Doneckoe klinicheskoe territorial'noe medicinskoe ob'edinenie
Abstract
An assessment of genetic factors influence on ibandronic acid effect in postmenopausal osteoporosis treatment can significantly bring us closer to the practical use of this results in prognostic genetics and personalized medicine. The aim was the study of associations between 283 A>G (BsmI, rs1544410) polymorphisms of vitamin D receptor gene (VDR) and ibandronic acid efficacy in postmenopausal osteoporosis treatment.
117 women with postmenopausal osteoporosis were examined through treatment dynamics. A 12-month therapy course included the use of ibandronic acid according to standard regimen. Evaluation of treatment effectiveness was carried out by changes (%) in bone mineral density (BMD) separately for each area by dual- energy X-ray absorptiometry. Real-time PCR was used to determine VDR gene rs1544410 polymorphism.
It was found that for 12 months ibandronate use caused significant (p<0.001) BMD increase. BMD increase ranged from 2.71±0.53% in left femoral neck zone to 4.63±0.53% in the L1-L4 lumbar vertebrae. The treatment outcome did not depend (p>0.05) on age, height, weight, body mass index, and postmenopause duration. GG genotype of rs1544410 polymorphism was associated with lower BMD growth rate in L1-L4 lumbar vertebrae (p=0.036).
Screening of women with postmenopausal osteoporosis for polymorphic variants of VDR gene (rs1544410) before antiresorptive therapy with ibandronic acid may be appropriate to predict the effect and individualize treatment and prophylactic measures. The obtained results can contribute to more complete understanding of osteoporosis pharmacogenetics
Publisher
RIOR Publishing Center
Subject
Process Chemistry and Technology,Economic Geology,Fuel Technology
Reference16 articles.
1. Langdahl B. L. Overview of treatment approaches to osteoporosis. Br. J. Pharmacol. 2020. Epub ahead of print. doi:10.1111/bph.15024, Langdahl B. L. Overview of treatment approaches to osteoporosis. Br. J. Pharmacol. 2020. Epub ahead of print. doi:10.1111/bph.15024 2. Захаров И. С., Колпинский Г. И., Шаламанова Н. В., Колесник И. Ю., Лебедева Т. В., Титаренко О.В. Комплексный подход к терапии остеопороза в постменопаузальном периоде в контексте международных клинических рекомендаций. Consilium Medicum. 2019;21(6):50-53. doi:10.26442/20751753. 2019.6.190530, Zaharov I. S., Kolpinskiy G. I., Shalamanova N. V., Kolesnik I. Yu., Lebedeva T. V., Titarenko O.V. Kompleksnyy podhod k terapii osteoporoza v postmenopauzal'nom periode v kontekste mezhdunarodnyh klinicheskih rekomendaciy. Consilium Medicum. 2019;21(6):50-53. doi:10.26442/20751753. 2019.6.190530 3. Marozik P., Alekna V., Rudenko E., Tamulaitiene M., Rudenka A., Mastaviciute A., Samokhovec V., Cernovas A., Kobets K., Mosse I. Bone metabolism genes variation and response to bisphosphonate 2020, том 23, № 1 ТАВРИЧЕСКИЙ МЕДИКО-БИОЛОГИЧЕСКИЙ ВЕСТНИК treatment in women with postmenopausal osteoporosis. PLoS One. 2019;14(8): e0221511. doi:10.1371/journal. pone.0221511, Marozik P., Alekna V., Rudenko E., Tamulaitiene M., Rudenka A., Mastaviciute A., Samokhovec V., Cernovas A., Kobets K., Mosse I. Bone metabolism genes variation and response to bisphosphonate 2020, tom 23, № 1 TAVRIChESKIY MEDIKO-BIOLOGIChESKIY VESTNIK treatment in women with postmenopausal osteoporosis. PLoS One. 2019;14(8): e0221511. doi:10.1371/journal. pone.0221511 4. Монахова А. И., Егорова Е. В., Лялина В. В., Сторожаков Г. И. Фармакогенетика бисфосфонатов в лечении постменопаузального остеопороза. Обзор литературы. Лечебное дело. 2013;3:53-8., Monahova A. I., Egorova E. V., Lyalina V. V., Storozhakov G. I. Farmakogenetika bisfosfonatov v lechenii postmenopauzal'nogo osteoporoza. Obzor literatury. Lechebnoe delo. 2013;3:53-8. 5. Lуpez-Delgado L., Riancho-Zarrabeitia L., Riancho J.A. Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis. Expert. Opin. Drug. Metab. Toxicol. 2016;12(4):389-98., Lupez-Delgado L., Riancho-Zarrabeitia L., Riancho J.A. Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis. Expert. Opin. Drug. Metab. Toxicol. 2016;12(4):389-98.
|
|